Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jamie Acquaviva, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, and Keizo Koya

Synta Pharmaceuticals Corp., Lexington, MA

Running Title: Preclinical characterization of ganetespib

Keywords: ganetespib, Hsp90 inhibition, antitumor, oncoproteins, cancer therapy

Abbreviations List: Hsp90, heat shock protein 90; 17-AAG, 17-allylamino-17-demethoxygeldanamycin; 17-DMAG, 17-dimethylaminoethylamino-17-demethoxygeldanamycin; GA, geldanamycin; TKI, tyrosine kinase inhibitor, HNSTD, highest non-severely toxic dose; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; NSCLC, non-small cell lung cancer; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

Financial Support: All work was funded by Synta Pharmaceuticals Corp.

Corresponding author information: Weiwen Ying, Synta Pharmaceuticals, Corp., 45 Hartwell Avenue, Lexington, MA 02421. Phone: 781-541-7243; Fax: 781-274-8228; Email: wying@syntapharma.com

Disclosure of Potential Conflicts of Interest: All authors are current or former employees of Synta Pharmaceuticals, Corp.

Word Count: 5137      Figures/Tables: 6
Abstract

Targeted inhibition of the molecular chaperone heat shock protein 90 (Hsp90) results in the simultaneous blockade of multiple oncogenic signaling pathways and has thus emerged as an attractive strategy for the development of novel cancer therapeutics. Ganetespib (formerly known as STA-9090) is a unique resorcinolic triazolone inhibitor of Hsp90 currently in clinical trials for a number of human cancers. Here we show that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematological tumor cell lines, including those that express mutated kinases that confer resistance to small molecule tyrosine kinase inhibitors (TKIs). Ganetespib treatment rapidly induced the degradation of known Hsp90 client proteins, displayed superior potency to the ansamycin inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG), and exhibited sustained activity even with short exposure times. In vivo, ganetespib demonstrated potent antitumor efficacy in solid and hematological xenograft models of oncogene addiction, as evidenced by significant growth inhibition and/or regressions. Of note, evaluation of the microregional activity of ganetespib in tumor xenografts showed that ganetespib efficiently distributed throughout tumor tissue, including hypoxic regions >150 μm from the microvasculature, to inhibit proliferation and induce apoptosis. Importantly, ganetespib showed no evidence of cardiac or liver toxicity. Taken together, this preclinical activity profile suggests that ganetespib may have broad application for a variety of human malignancies, and with select mechanistic and safety advantages over other first- and second-generation Hsp90 inhibitors.
Introduction

Heat shock protein 90 (Hsp90) is a molecular chaperone that regulates the post-translational folding, stability and function of its protein substrates ("client" proteins), many of which play critical roles in cell growth, differentiation and survival (1, 2). As with other physiological processes that become co-opted by tumor cells, it is now clear that the chaperoning functions of Hsp90 can become subverted during tumorigenesis to facilitate malignant progression (1). The Hsp90 machinery serves as a biochemical buffer for a number of oncogenic signaling proteins causally implicated in a variety of tumors (3, 4). Often, these oncoproteins are expressed as mutant forms that are particularly reliant on Hsp90 for stability and function (5, 6). Cancer cells contain elevated levels of the active form of the Hsp90 complex relative to normal cells, and have been shown to be selectively sensitive to Hsp90 inhibition (7, 8). Moreover, a unique characteristic of targeting Hsp90 is that inhibition results in the combinatorial blockade of multiple signal transduction cascades, thereby potentially bypassing pathway redundancies often found in cancer cells (9-11). Thus, Hsp90 represents an attractive molecular target for the development of novel cancer therapeutics (4, 11, 12).

The first class of Hsp90 inhibitors to be characterized were the benzoquinone ansamycins, including geldanamycin (GA) and its derivatives 17-allylamino-17-demethoxygeldanamycin (17-AAG), and 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) (13). However the clinical progression of this group has been hampered due to several drawbacks including poor solubility, formulation problems, potential multidrug efflux, and hepatotoxicity (13, 14). In addition, as single agents these inhibitors have only shown modest efficacies in the clinical setting (15, 16), suggesting that they may be most effective as combination therapies. In an effort to overcome these limitations, several second generation synthetic Hsp90 inhibitors representing multiple drug classes are currently under development (17-23).
Here we describe the preclinical characterization of ganetespib (formerly known as STA-9090), a novel small molecule inhibitor of Hsp90 with a unique triazolone-containing chemical structure. Key pharmacologic and biological properties of ganetespib distinguish this compound from other first- and second-generation Hsp90 inhibitors in terms of potency, antitumor activity and an improved safety profile resulting in a superior therapeutic index. Accordingly, ganetespib is currently being evaluated in multiple Phase I and II clinical trials. Taken together, these results support the continued development of ganetespib as a novel therapeutic agent for a variety of human cancers.
Materials and Methods

Cell lines, antibodies and reagents

All cell lines were obtained from the ATCC (Rockville, MD) and maintained according to standard techniques. The cell lines were authenticated by the routine ATCC routine Cell Biology Program using short tandem repeat (STR) analysis (DNA profiling) and were used within 6 months of receipt for this study. All primary antibodies were purchased from Cell Signaling Technology (CST, Beverly, MA). Ganetespib [3-(2,4-dihydroxy-5-isopropylphenyl)-4-(1-methyl-1H-indol-5-yl)-1H-1,2,4-triazol-5(4H)-one] was synthesized by Synta Pharmaceuticals Corp. 17-AAG, 17-DMAG and erlotinib were purchased from LC Laboratories (Woburn, MA). Purified Hsp90 protein was obtained from Stressgen (Victoria, Canada) and recombinant human HGF from R&D Systems (Minneapolis, MN).

Cell viability assays

Cells were grown in 96-well plates based on optimal growth rates determined empirically for each line. Twenty four hours after plating cells were treated with the indicated compounds or controls for 72 h. AlamarBlue (Invitrogen, Carlsbad, CA) was added (10% v/v) to the cells, and the plates incubated for 3 h and subjected to fluorescence detection. For the comparative viability/apoptosis assay, NCI-H1975 cells were treated with escalating concentrations of ganetespib for the indicated time periods and subject to viability analysis via CellTitre Fluor (Promega, Madison WI) and apoptosis via Caspase Glo 3/7 (Promega).

Western blotting

Following treatment, tumor cells were disrupted in lysis buffer (CST) on ice for 10 min. Lysates were clarified by centrifugation and equal amounts of proteins resolved by SDS-PAGE before
transfer to nitrocellulose membranes (Invitrogen, Carlsbad CA). Membranes were blocked with 5% skim milk in TBS with 0.5% Tween and immunoblotted with the indicated antibodies. The antibody-antigen complex was visualized and quantitated using an Odyssey system (LI-COR, Lincoln, NE).

**In vivo xenograft tumor models**

Female immunodeficient Crl:CD1-Foxn1^nu^ (nude) and CB-17/lcr-Prkdc^scid^/Crl (SCID) mice (Charles River Laboratories, Wilmington, MA) were maintained in a pathogen-free environment, and all *in vivo* procedures were approved by the Synta Pharmaceuticals Corp. Institutional Animal Care and Use Committee. NCI-H1395 and MV4-11 cells were subcutaneously implanted into SCID mice and MKN45 cells into nude mice. Mice bearing established tumors (100-200 mm^3^) were randomized into treatment groups of 8 and i.v. dosed via the tail vein with either vehicle or ganetespib formulated in 10/18 DRD (10% DMSO, 18% Cremophor RH 40, 3.6% dextrose, 68.4% water). In the NCI-H1395 model, studies were conducted at the highest non-severely toxic doses of 150 mg/kg weekly; in the MV4-11 model, animals were treated with ganetespib at 100 and 125 mg/kg weekly; in the MKN45 model, animals were treated with ganetespib at 50 mg/kg 3 times a week. Tumor growth inhibition was determined as described previously (24).

**Microregional activity of ganetespib in NCI-H1975 xenografts**

NCI-H1975 tumor xenograft implanted SCID mice were treated with 125 mg/kg ganetespib for 6-72 h. At the end of the experiment mice were administered BrdUrd and pimonidazole to label S phase cells and hypoxic tumor regions and then 5 min prior to excision mice were administered DiOC7 to demarcate perfused vessels. Following tumor excision and freezing, 10 μm thick cryosections were cut and sequentially immunostained to detect markers of proliferation (BrdUrd), apoptosis (TUNEL), hypoxia (HIF-1α), and tumor vasculature (CD31). Images of CD31 fluorescence, BrdUrd and TUNEL staining from each section were overlaid and areas of necrosis...
and staining artifacts manually removed. Proliferation and apoptosis were plotted as a function of distance from vessels.

**Hepatotoxicity assay**

Male Sprague Dawley rats were treated with repeated daily administration of escalating doses of 17-DMAG (formulated in 5% dextrose in water) or ganetespib (formulated in DRD). Blood serum was collected during necropsy at the end of the experiment in all rats treated with or without testing compound. The serum liver enzyme tests were performed at IDEXX Laboratories (North Grafton, MA) according to their validated standard operation procedure. For histological analysis, livers were removed at necropsy and formalin fixed. Paraffin embedded sections were processed and stained with hematoxylin-eosin for routine histology evaluation.

**Langendorff assay**

Briefly, hearts from male New Zealand white rabbits were used to measure the physiological variables PQ, QRS, RR, QT, and dLVP/dt following perfusion with escalating doses of ganetespib ($10^{-8} – 10^{-4}$ M) (see Supplementary Materials and Methods for complete details). Mean values for each parameter were calculated for each concentration, and mean values ($\pm$SEM) were plotted against concentration for all parameters assessed, both for ganetespib-exposed and vehicle-treated hearts.
Results

Ganetespib binds to the N-terminal ATP binding site in Hsp90

Ganetespib is a novel resorcinolic triazolone compound that is structurally distinct to the first-generation ansamycin Hsp90 inhibitors. The chemical structure is shown in Fig. 1A. With a molecular weight of 364.4, ganetespib is considerably smaller than the ansamycin class, and most of the newer, second generation Hsp90 inhibitors. Ganetespib is relatively hydrophobic, with a cLogP value of 3.3. Ganetespib exhibits competitive binding for the ATP pocket at the N-terminus of Hsp90. There are reports that the N-terminus can be crystallized in a number of conformations including an ‘open’ or ‘closed’ conformation in reference to the position of the ATP binding pocket lid (25). We have obtained the co-crystal structure of ganetespib bound to the ‘closed’ conformation of the Hsp90 N-terminus (Fig. 1B), however we anticipate that ganetespib can also access the ATP pocket in the ‘open’ conformation based on computational analysis (data not shown).

The X-ray co-crystal structure of ganetespib bound to Hsp90 (Fig. 1C) confirmed important hydrogen bonding interactions, also seen in the ansamycin family, involving the resorcinol hydroxyl group with Asp93 and the carbonyl group of triazolone with Lys58. Importantly, in ganetespib, the 2-hydroxyl of resorcinol is within hydrogen bond distance to both oxygen atoms of the carboxylic group in Asp93, resulting in a substantially stronger interaction. Further, the N2 of triazolone forms a water-bridged hydrogen bond with Asp93 to provide additional hydrogen bonding. Water bridge hydrogen bonds between 4-hydroxyl of resorcinol and Leu48 and Ser52 were found to be critical for binding efficiency in our optimization efforts. The hydrazinecarboxamide moiety of triazolone in ganetespib is of particular structural importance. In addition to the direct hydrogen bond with Lys58, it forms a unique hydrogen bond with Gly97, a distinguishing feature from the ansamycin analogs. Further, it also interacts with Thr184 and Asp102 through water bridge hydrogen bonding (Fig. 1C).
Ganetespib displays superior potency to 17-AAG in a broad range of tumor cells

The in vitro cytotoxic activity of ganetespib was determined against a panel of 57 transformed cell lines derived from both hematological and solid tumors and compared to that of 17-AAG (Supplementary Table 1). Ganetespib was potently cytotoxic in the majority of the lines examined, typically with IC₅₀ values in the low nanomolar range. Overall, ganetespib demonstrated a 20-fold greater potency than 17-AAG with median IC₅₀ values of 14 nM vs. 280 nM, respectively. This difference in sensitivity was even more pronounced in the subset of hematological malignancies, which showed a 47.5 fold difference (median IC₅₀ values of 10 nM vs. 475 nM). Indeed, leukemic cell lines (AML, CML, B cell lymphoma, ALCL) manifested the greatest sensitivity to ganetespib treatment, while melanoma and prostate represented tumor types in which ganetespib was also highly cytotoxic (Supplementary Table 1). Of note, ganetespib retained potency against cell lines expressing mutated kinases that confer resistance to kinase inhibitors currently in clinical practice.

Ganetespib induces cell cycle arrest and apoptosis

Cell cycle analysis showed that ganetespib induced marked accumulation in the G₂/M phase within 24 h in NCI-H1975 cells, with a concomitant loss of S phase (Supplementary Fig. 1). The viable cell population remained blocked for at least 72 h; however, over this period, the percentage of apoptotic cells increased. To confirm this, cells were exposed to increasing concentrations of ganetespib for 6 to 72 h. Apoptosis was measured using activated caspase 3/7 levels and compared to cell viability (Fig. 2A). No effects were seen 6 h after treatment. However, the marked loss of viability following exposure to ganetespib observed 24-48 h post-treatment correlated with increased apoptotic induction. These results suggest that ganetespib-induced cytotoxicity is mediated by an irreversible commitment to apoptosis, which is likely subsequent to growth arrest and effects on the cell cycle (24).
Ganetespib exhibits sustained activity with short exposure times

We then investigated the exposure time of ganetespib required to induce cytotoxic responses in vitro using the NCI-H1975 and HCC827 NSCLC lines. Cells were exposed to ganetespib for the indicated times (5 min, 15 min, 60 min and 24 h), washed to remove the drug, and then grown in standard medium until cell viability was measured at 72 h (Fig. 2B). Unexpectedly, exposure to ganetespib for only 60 min resulted in cytotoxicity IC₅₀ values of 510 nM and 800 nM for NCI-H1975 and HCC827 cells, respectively (Supplementary Table 2). Remarkably, a 5 min exposure to ganetespib in NCI-H1975 cells still resulted in an IC₅₀ value < 1 μM, a plasma concentration that is achievable in vivo. These findings indicated that cell viability was quickly affected by ganetespib treatment, and suggest that even brief drug exposure may be sufficient to affect tumor growth.

Ganetespib displays potent activity against drug-resistant tumor phenotypes in vitro

In NSCLC activating mutations in EGFR can drive tumorigenesis and confer sensitivity to tyrosine kinase inhibitors (TKIs) such as erlotinib and gefitinib (26). To examine whether ganetespib could overcome the resistant phenotype in NSCLC cells, we compared the activity of ganetespib and erlotinib (Supplementary Fig. 2) using the NCI-H1975 cell line, which expresses a mutationally activated and erlotinib-resistant EGFR L858R/T790M mutation, and erlotinib-sensitive HCC827 cells, which express EGFR Del E746_A750 (Fig. 3A). As expected, erlotinib treatment resulted in dose-dependent cytotoxicity in HCC827 cells, but had no effect on NCI-H1975 cells. In contrast, ganetespib exhibited full potency against both cell lines, irrespective of EGFR mutational status.

Resistance to EGFR inhibitors may also emerge through alternative oncogenic mechanisms. Hepatocyte growth factor (HGF), a ligand of the c-MET oncoprotein, can induce TKI resistance in lung tumors with EGFR-activating mutations by independently activating and restoring PI3K/AKT signaling via phosphorylation of c-MET (27, 28). Given that EGFR, c-MET and AKT are all Hsp90
client proteins, we therefore determined whether ganetespib was active against c-MET-induced TKI-resistant cells. HCC827 cells were seeded in the presence or absence of HGF (50 ng/ml) and 24 h later were dosed with ganetespib or erlotinib. Cell viability was assessed 72 h after drug addition (Fig. 3B). Both ganetespib and erlotinib were highly potent in non-stimulated HCC827 cells, with IC₅₀ values of approximately 10 nM. Importantly, while HGF-treated cells did not respond to erlotinib, ganetespib retained its potency in the presence of the growth factor. Similar results were observed in HCC827 cells selected for MET amplification (data not shown).

To examine modulation of MET-driven AKT signaling by ganetespib, HCC827 cells seeded with or without HGF for 24 h were treated with ganetespib or erlotinib at either 10 or 100 nM doses (which represent the IC₅₀ and IC₁₀₀ drug concentrations, respectively). Cells were harvested at 24 h and levels of MET, EGFR, and their relevant effectors were examined by Western blot (Fig. 3C). Ganetespib treatment promoted the down-regulation of MET, EGFR, and AKT protein levels in both the absence and presence of HGF, resulting in the complete loss of AKT and ERK activity. Erlotinib exposure was capable of inactivating AKT and ERK in the absence of HGF, but was ineffective in the presence of the growth factor.

**Ganetespib exhibits potent in vivo activity in both solid and hematological xenograft models**

To determine whether the effects of ganetespib in vitro translate to antitumor efficacy in vivo, the activity of ganetespib was evaluated using a variety of doses and schedules in a series of xenograft models. Initially, SCID mice bearing NCI-H1395 NSCLC xenografts were dosed intravenously (i.v.) with ganetespib on a weekly schedule at its highest non-severely toxic dose (HNSTD) of 150 mg/kg (Fig. 4A). NCI-H1395 tumor regression was induced by ganetespib with a T/C value of -49% compared with the control group. Importantly, this regimen was well tolerated with minimal loss of body weight observed during the course of treatment (Fig. 4B).
MV4-11 acute myeloid leukemia (AML) cells express the Hsp90 client protein FLT3, an oncogenic driver and the most common genetic alteration associated with AML (29). This cell line is highly sensitive to ganetespib in vitro (IC_{50} value of 4 nM, Supplementary Table 1). Ganetespib was administered i.v. to MV4-11 tumor-bearing SCID mice once weekly at 100 mg/kg and 125 mg/kg. As shown in Fig. 4C, these two treatment regimens resulted in significant tumor regression (85% and 94%, respectively). Moreover, tumors were undetectable in 37.5% of ganetespib treated animals at the end of the 3 week dosing period.

Amplification of the c-MET receptor tyrosine kinase occurs in approximately 20% of gastric carcinomas (30). We therefore used the human c-MET amplified MKN45 gastric carcinoma cell line as an additional xenograft model of oncogene addiction to examine the antitumor activity of ganetespib (Fig. 4D). Ganetespib treatment was again highly efficacious in this study, with a 50 mg/kg dose 3 times per week resulting in 92% inhibition of tumor growth.

**Ganetespib penetrates hypoxic regions of tumors in vivo**

To evaluate tumor penetration, the microregional activity of ganetespib was assessed in NCI-H1975 tumor xenografts. Immunohistochemical markers of proliferation (bromodeoxyuridine), apoptosis (TUNEL) and hypoxia (HIF-1α) in tumors were mapped in relation to distance from the nearest CD31⁺ endothelial cells (Fig. 5). A single dose of ganetespib at 125mg/kg dramatically reduced cellular proliferation throughout the tumors, with the maximal effect occurring 24 h following treatment (Fig. 5A). Further, a concomitant induction of tumor cell apoptosis occurred within 24 h (Fig. 5B). Moreover, at 6 h, apoptosis was preferentially induced near vessels and then became uniformly induced throughout the tissue by the 48 h time point (data not shown). Increased HIF-1α staining as a function of distance confirmed the hypoxic gradient that existed within the tumors and, importantly, this Hsp90 client protein was potently suppressed in vivo following treatment with ganetespib (Fig. 5C). These results provide strong evidence that ganetespib efficiently distributed within the extravascular compartment, including the hypoxic...
regions >150 μm from the microvasculature, resulting in sustained inhibition of proliferation and induction of apoptosis throughout the tumors.

**Ganetespib exhibits a favorable safety profile**

The hepatotoxicity profile of ganetespib was evaluated in male Sprague Dawley rats based on changes in the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) (Fig. 6A). Animals were treated with repeated administration of ganetespib at 25, 50 and 75 mg/kg/d for 5 days, or 17-DMAG (Supplementary Fig. 2) at 2, 4, and 6 mg/kg/d for 4 days. No changes in the levels of either enzyme were observed in the ganetespib-treated animals, even at the highest dose of 75 mg/kg, which is higher than the efficacious dose range for this compound. The 75 mg/kg dose represented the effective maximum tolerated dose in these animals, as extensive GI toxicity was observed following the 5 day treatment. In stark contrast, a dose-dependent and marked elevation of ALT (293% - 510%) and AST (149% - 296%) was seen with 17-DMAG treated rats, at doses 12.5 times lower than ganetespib. Histologic analysis (Fig. 6B) revealed that livers of animals treated with 17-DMAG at the lowest 2 mg/kg dose showed patchy and focal hepatocytic apoptosis with mild mononuclear cell infiltration. At the 6 mg/kg dose, the lesions were diffuse and severe, including larger areas of coagulative hepatocytic necrosis. These injuries were primarily observed in the area near the central vein of the hepatic plate and are consistent with the elevated levels of liver enzymes. In accordance with the lack of enzymatic induction, there were no discernable morphologic changes in the hepatocytes of animals treated with ganetespib.

Cardiovascular effects of escalating doses ganetespib on electrophysiological (PQ, QRS, RR and QTc) and mechanical (left ventricular developed pressure) properties were evaluated in isolated New Zealand white rabbit hearts. Ganetespib exerted no significant physiological effects other than a minimal reduction in AV conduction (lengthening PQ interval) and a minor reduction in heart rate (increased RR interval) over the concentrations 10^{-8}–10^{-5} M (data not shown).
was no change in the QTc(F) intervals at concentrations of ganetespib between $10^{-8}$ to $10^{-5}$M when compared to baseline or vehicle (Fig. 6C). Similarly, there was no change in the QRS duration after exposure to concentrations of ganetespib ranging from $10^{-8}$ to $10^{-6}$ M, when compared to baseline or vehicle; however an increase in the duration of the QRS was noted after exposure to the $10^{-5}$ M concentration (Fig. 6C). At $10^{-4}$ M, the highest concentration tested, ganetespib lengthened PQ interval and QRS duration, however this concentration was approximately 3000 fold higher than the unbound $C_{\text{max}}$ in the 125mg/kg dose in the NCI-H1975 tumor penetration studies (Figure 5). Other cardiac electrophysiological parameters and mechanical properties, including left ventricular developed pressure, were not significantly altered following exposure to ganetespib, while expected physiological changes with the positive control quinidine were observed (data not shown).
Discussion

In this study we provide the first preclinical characterization of ganetespib, a novel and potent inhibitor of Hsp90 that offers considerable promise as a new targeted cancer therapeutic. Structurally, ganetespib is distinct to the first-generation ansamycin Hsp90 inhibitors, with a unique scaffold that is considerably smaller than these GA analogs. Hsp90 chaperone activity is associated with an ATP-driven conformational change within the N-terminal domain (31, 32). Our data show that ganetespib is able to enter the ATP binding pocket in the so-called ‘closed’ conformation. In contrast, due to their larger size the ansamycin analogs can only occupy the ATP binding pocket in the ‘open’ conformation. For clarity, this discussion of ‘open’ and ‘closed’ conformation of the Hsp90 N-terminal refers to the positioning of the ATP pocket lid, which is different from the ‘open and closed’ concept in Hsp90 chaperoning cycle involving dimerization (33). This lack of restriction for binding to the Hsp90 ATP pocket may be one of the reasons that ganetespib demonstrates higher \textit{in vitro} potency compared to the GA analogs. Also, our structural analysis has identified a series of additional hydrogen bond interactions due to the presence of the triazolone moiety that predict for superior binding affinities between ganetespib and Hsp90, further distinguishing this compound from the GA class.

Human cancers are typically characterized by a variety of genetic alterations that collectively contribute to the transformed state, however a subset are now believed to be dependent on single, definable oncogenic pathways for their genesis, proliferation and/or survival. This phenomenon is known as oncogene addiction (34) and, because a large number of the addicting oncoproteins are known Hsp90 clients, this has important implications for the development of targeted therapeutics. The panel of solid and hematological tumor lines found to be sensitive to ganetespib was derived from diverse tissue origins. Notably, many of the most acutely sensitive lines harbored activating mutations or amplifications of these oncoproteins, including EGFR, c-MET, BCR-ABL, B-RAF, c-KIT, and HER2, consistent with the hypothesis that these oncogenic drivers are more reliant on Hsp90 for their stability and function (35). The \textit{in vitro} activity of
ganetespib translated to potent antitumor efficacy in a series of xenograft models selected for their dependence on such oncogenic pathways for growth. Ganetespib also exhibited robust cellular potency against drug resistant tumor phenotypes, overcoming molecular alterations in NSCLC lines that confer clinical resistance to a number of small molecule TKIs. Furthermore, we discovered that even brief exposure to ganetespib (as little as 5 to 60 min) resulted in potent cytotoxic responses in NSCLC cells with IC_{50} values readily achievable in vivo. Emerging evidence from the use of small molecule TKIs in a variety of human cancers suggests that transient, potent oncogene inhibition can be sufficient to induce clinically relevant effects on cellular viability (36, 37). Taken together these findings strongly suggest that ganetespib is likely to have broad therapeutic utility in a variety of human malignancies and suggest that the durable response property of ganetespib may support the use of intermittent dosing schedules in the clinic.

With its unique chemical structure, ganetespib exhibited several key pharmacologic and biological properties sufficient to account for the potent antitumor responses observed. The compound has relatively high lipophility which, along with its smaller size, would be expected to facilitate transport across lipid membranes and into cells. In xenograft bearing animals ganetespib showed selective retention in tumor tissue with similar kinetics as those reported for other resorcinolic Hsp90 inhibitors (38). The most important observation, however, was that the physicochemical properties of the compound resulted in extensive penetration and distribution of ganetespib throughout tumors, including hypoxic regions distal to the nearest blood vessels. From a clinical perspective, the effectiveness of many anticancer agents can be compromised by limited drug distribution, as efficient penetration is necessary to reach the target population and in concentrations sufficient to exert a therapeutic effect (39). In this regard, ganetespib treatment rapidly and dramatically reduced proliferation and induced apoptosis in xenograft tissues independent of the distance from the microvasculature. The capacity of ganetespib to penetrate the extravascular compartment of solid tumors combined with its extended tumor retention and cellular potency clearly predicts for maximal efficacy.
Overall unfavorable safety profiles, including hepatotoxicity, have hampered the clinical application of the ansamycin class of Hsp90 inhibitors. There the chemical reactivity of the benzoquinone group appears accountable for the observed elevation of liver enzymes and associated liver toxicity in the clinical setting (4). Consistent with the findings for other rationally designed second-generation inhibitors, ganetespib showed no evidence of liver toxicity in the preclinical assessment of changes in liver enzymes or histopathology. Cardiac toxicity is also potential risk factor for many classes of drugs, in part due to adverse effects on critical ion channels that regulate heart beat (37). Our cardiovascular analysis revealed that the two predominant effects attributable to exposure to ganetespib in the Langendorff assay were a slight dose-dependent lengthening of the PQ interval and a minor change in QRS duration at the $10^{-5}$ M concentration. Moreover, the observation that the QTc interval did not lengthen is consistent with ganetespib having no effect on ventricular repolarization. Together with no significant alterations in other electrophysiological and mechanical parameters, ganetespib therefore exhibits a favorable cardiotoxic profile. Importantly, our safety studies were performed to maximally tolerated doses and no other adverse events were seen to suggest that ganetespib manifests any additional toxicities. Of note, ocular toxicities have recently emerged as an undesirable side-effect for the newer synthetic Hsp90 inhibitors (40). To date, over 400 patients have been treated with ganetespib, and an absence of ocular toxicity is evident (<3%, W. Ying, unpublished observation). Currently a comprehensive profiling of ganetespib and other Hsp90 inhibitors for potential CNS or ocular toxicity risks is underway.

In summary, we have developed and characterized a unique small-molecule Hsp90 inhibitor that exhibits potent and sustained antitumor effects in a broad range of malignancies both \textit{in vitro} and \textit{in vivo}. Importantly, ganetespib retained its potency against tumor phenotypes that confer drug resistance to agents currently in use in the clinic. In addition, ganetespib displays optimal pharmacological properties including high tumor penetration and a favorable safety profile that
predict for a superior therapeutic index. Accordingly, ganetespib represents an exciting new targeted agent for the treatment of human cancers.
Acknowledgments

We thank Tim Koburt, Donald Smith, Chaohua Zhang and Yuan Liu for their excellent technical assistance and dedication to the project and to Richard Bates who provided drafts and editorial assistance during preparation of this manuscript.
References


Figure Legends

Figure 1. Chemical structure of ganetespib and its co-crystal structure with Hsp90 N-terminal. A, Chemical structure of ganetespib. B, Crystallographic complex of ganetespib in the Hsp90 N-terminal. C, Hydrogen bond interactions between ganetespib with amino acid residues in the Hsp90 N-terminal ATP binding pocket.

Figure 2. Ganetespib induces apoptosis in human cancer cells in vitro. A, NCI-H1975 cells were treated with increasing concentrations of ganetespib for 6, 24, 48 and 72 h, and then subject to analysis of viability and apoptosis. The IC$_{50}$ values for viability at 6, 24, 48 and 72 h were >1000 nM, >1000 nM, 16 nM and 8 nM, respectively. B, NCI-H1975 and HCC827 cells were exposed to graded concentrations of ganetespib for 5, 15, 60 min and 24 h. Cell viability was assessed 72 h following drug wash-out.

Figure 3. Ganetespib exhibits potency against erlotinib-resistant NSCLC tumor phenotypes in vitro. A, NCI-H1975 and HCC827 cells were treated with increasing concentrations of ganetespib or erlotinib and cell viability was assessed after 72 h. B, HCC827 cells were seeded in the presence or absence of HGF (50 ng/mL) for 24 h, then exposed to graded concentrations of ganetespib or erlotinib for 72 h. Cell viability was measured by AlamarBlue. C, HCC827 cells seeded with or without 50 ng/mL HGF for 24 hr were treated with 0, 10 or 100 nM ganetespib or erlotinib for an additional 24 h. The levels of MET, EGFR, ErbB3, total (T-) AKT, p-AKT, p-ERK1/2, and GAPDH were analyzed by Western blot.

Figure 4. Ganetespib exhibits potent antitumor efficacy in oncogene-driven xenograft models of solid and hematological malignancies. Xenografts 100-200 mm$^3$; n = 8 mice/group. % T/C values are indicated to the right of each growth curve and the error bars are the SEM. A, Mice bearing established NCI-H1395 xenografts were i.v. dosed with ganetespib at 150 mg/kg once weekly as indicated (arrowheads). B, Body weights were measured 5 times per week. Mean values are
plotted against vehicle controls. C, Mice bearing established MV4-11 xenografts were i.v. dosed with ganetespib at 100 and 125 mg weekly as indicated (arrowheads). D, Mice bearing established MKN45 xenografts were i.v. dosed with ganetespib at 50 mg/kg three times per week as indicated (arrowheads).

**Figure 5.** Tumor penetration and microregional activity of ganetespib. A single 125 mg/kg dose of ganetespib was administered i.v. to established NCI-H1975 xenografts and tumors (n = 8/group) were removed 24 h after treatment. Immunohistochemistry was performed on cryosections for markers of proliferation (bromodeoxyuridine) and apoptosis (TUNEL). A, Proliferation was mapped in relation to distance from the nearest CD31+ endothelial cells. 100% of tumor cells were located <170 μm from the nearest blood vessels. B, Apoptosis was mapped in relation to distance from the nearest CD31+ cells. C, HIF-1α expression was mapped in relation to distance from the nearest CD31+ cells.

**Figure 6.** Liver and cardiovascular effects profile of ganetespib. A, Male Sprague Dawley rats (n = 3-5 rats/group) were treated with repeated administration of 17-DMAG at 2, 4 and 6 mg/kg for 4 days (qd x 4) or ganetespib at 25, 50 and 75 mg/kg for 5 days (qd x 5). Plasma levels of the liver enzymes aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are presented. B, Hematoxylin and eosin (H&E) staining of liver cross sections from vehicle control, 17-DMAG, or ganetespib treated animals. Original magnification, 200X (second panel 400X). C, Effects of escalating doses of ganetespib and vehicle on the QTc(F) interval (left panel) and QRS interval (right panel) in male rabbit hearts. Ganetespib values presented as the mean (±SEM); n=6, except n=2 at 10^{-8} M and n=4 at 10^{-6} M. No measurements were possible at 10^{-4} M due to arrhythmias. Due to formulation procedure differences, four hearts were perfused with concentrations of 10^{-7}-10^{-4} M. The remaining two hearts were perfused with concentrations of 10^{-8}-10^{-4} M. Therefore the vehicle time points in parentheses in the figure correspond to when the four test hearts differ from the two test hearts. Vehicle values are presented from one animal.
Figure 2

A

**A**

![Graphs showing apoptosis and viability](graph1.png)

- **Apoptosis** and **Viability**
- **6h**
- **24h**
- **48h**
- **72h**

B

**B**

![Graphs showing % viability](graph2.png)

- **NCI-H1975**
- **HCC827**

Downloaded from mct.aacrjournals.org on April 4, 2017. © 2011 American Association for Cancer Research.
Figure 4

A) H1395 NSCLC

B) Days After Implantation

C) MV4-11 AML

D) MKN45 Gastric Carcinoma

Days After Tumor Implantation

i.v. Dosing (1X/week): ▲

Average Tumor Volume (mm³)

Average Weight Change (%)
Figure 6

Downloaded from mct.aacrjournals.org on April 4, 2017. © 2011 Am
Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy

Weiwen Ying, Zhenjian Du, Lijun Sun, et al.

Mol Cancer Ther Published OnlineFirst December 5, 2011.

Updated version
Access the most recent version of this article at: doi:10.1158/1535-7163.MCT-11-0755

Supplementary Material
Access the most recent supplemental material at: http://mct.aacrjournals.org/content/suppl/2011/12/08/1535-7163.MCT-11-0755.DC1

Author Manuscript
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.